Skip to Main Content

INFORMATION FOR

    Michael S. Leapman, MD, MHS

    Associate Professor of Urology
    DownloadHi-Res Photo

    Are You a Patient?

    View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    View Doctor Profile

    Additional Titles

    Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center

    Assistant Professor, Chronic Disease Epidemiology

    Contact Info

    Urology

    PO Box 208058

    New Haven, CT 06520-8058

    United States

    About

    Titles

    Associate Professor of Urology

    Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center; Assistant Professor, Chronic Disease Epidemiology

    Biography

    Clinical interests: Prostate cancer: elevated PSA, prostate cancer risk, genetic risk, low-risk prostate cancer, active surveillance, robotic prostatectomy, single port prostatectomy, DaVinci prostatectomy, nerve-sparing, pelvic fascia sparing prostatectomy, high-risk prostate cancer, pelvic lymph node dissection, biochemical recurrence, salvage therapy, risk stratification; molecular imaging; PSMA-PET; Watch a video with Dr. Michael Leapman >>

    Michael Leapman, MD, MHS, was drawn to urology by the opportunity to care for patients with urologic cancers. He aims, above all, to deliver the highest level of care with the utmost consideration and compassion for the impact cancer has on patients, their families, and their communities.

    Dr. Leapman is an Associate Professor and Vice Chair of Research in the Department of Urology at the Yale School of Medicine. He serves as Clinical Program Leader of the Prostate and Urologic Cancers Program at Yale Cancer Center and Smilow Cancer Hospital, and as Co-Leader of the Cancer Prevention and Control research program at Yale Cancer Center, where he is also a member of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center. He leads an active and highly productive research program examining how new diagnostic technologies are adopted into prostate cancer care, and what they mean for patients' outcomes, costs, and quality of care. His recent work includes national studies of active surveillance for early-stage prostate cancer and work estimating the longer-term outcomes associated with PSMA-PET imaging.

    Dr. Leapman graduated from Cornell University, where he majored in Neurobiology and Behavior, and received his medical degree from the University of Maryland in Baltimore. He earned a Master of Health Science degree from Yale University. He completed General Surgery and Urology training at the Mount Sinai Hospital in New York and a Society of Urologic Oncology fellowship in urologic oncology at the University of California, San Francisco and joined the Yale faculty in 2016.

    Last Updated on August 12, 2026.

    Appointments

    Other Departments & Organizations

    Education & Training

    MHS
    Yale University (2022)
    Fellowship
    University of California San Francisco (2016)
    Residency
    Mount Sinai Medical Center (2014)
    Internship
    Mount Sinai Medical Center (2010)
    MD
    University of Maryland School of Medicine (2009)
    BA
    Cornell University (2005)

    Research

    Overview

    Medical Research Interests

    Delivery of Health Care; Health Services Research; Kidney Diseases; Prostatic Neoplasms; Ureteral Diseases; Urinary Bladder Diseases; Urologic Neoplasms

    Research at a Glance

    Yale Co-Authors

    Frequent collaborators of Michael S. Leapman's published research.

    Publications

    2026

    Academic Achievements & Community Involvement

    Honors

    • honor

      John N. Forrest Jr. Prize for Mentorship in Student Research

    • honor

      Best Poster

    • honor

      Merit Award

    • honor

      First Place Essay, History Section

    • honor

      Outstanding Abstract Selected for Oral Presentation

    Clinical Care

    Overview

    Michael S. Leapman, MD, who specializes in prostate, bladder, testicular and kidney cancers, loves his work as a urologic oncologist.

    “Every day, I have the ability to make a difference in a patient's life,” says Dr. Leapman. “It's a tremendous honor and responsibility, and it's very rewarding.”

    A member of Yale Cancer Center, he sees patients at Smilow Cancer Hospital and the West Haven Veteran’s Administration. An assistant professor of urology at Yale School of Medicine, he studies the best treatments for prostate cancer and how gene expression signatures can predict the aggressiveness of this cancer.

    “Hearing the emotionally wrought words ‘it’s cancer’ is extremely difficult to navigate,” he says. “So that's one of the issues that we are sensitive to, and continue to strive to improve.”

    The patient-physician bond is essential in helping patients with prostate cancer, for example, to choose which kind of treatment is best: surgery, radiation therapy or active surveillance, an ongoing monitoring of what can be a slow-progressing disease.

    “It really is a very special relationship between a urologist and a patient. I have found that the team at Yale is 100 percent invested in the outcomes of our patients, and we stand out by seeking to understand their concerns, goals by being there for them every step of the way.”

    Clinical Specialties

    Urology; Urologic Oncology

    Fact Sheets

    Board Certifications

    • Urology

      Certification Organization
      AB of Urology
      Original Certification Date
      2018

    Yale Medicine News

    Get In Touch

    Contacts

    Appointment Number
    Clinical Inquiry Number
    Mailing Address

    Urology

    PO Box 208058

    New Haven, CT 06520-8058

    United States

    Locations

    • Patient Care Locations

      Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    Events

    Aug 202628Friday
    Sep 20264Friday
    Sep 202611Friday
    Sep 202618Friday